STNDWPI

Embed Size (px)

Citation preview

  • 7/27/2019 STNDWPI

    1/2

  • 7/27/2019 STNDWPI

    2/2

    REP NoSR.Pub ; EP 218010; US 4281065; US 4446065IC ICM C07K015-12; C07K015-14

    ICS A61K039-44; C07D211-06; C07D295-02; C07D307-00;C07D311-00;C07D493-10; C07K013-00; C07K015-16; C07K017-06;C12P021-08;G01N033-53

    AB EP 459387 A UPAB: 930928 Phencyclidene derivs. of formula (I)or (II) are new. W = CH or N. R = a linking gp. including up to 4heteroatoms selected from O, N, S, P or F and contg. a total of 0-8C and heteroatoms, and contg. 0 or 1 aliphatic or aromatic ringstructures. Z = NH, CO or CNH; n = 0 or 1, when W = N; or n = 1, \when W = CH. Q = poly(aminoacid) or a poly(amino acid) deriv. such asthyroglobulin. Also claimed is an antibody to (I) or (II). A processfor detecting phencyclidine and/or its metabolites in a sample is claimed,comprising:- (a) contacting the sample with antibodies and (I) or(II); (b) passing plane polarised light through the soln. to obtaina fluorescence polarisation response; and (c) detecting thefluorescence polarisation response. A kit for this process isprovided.USE/ADVANTAGE - (I) or (II) are tracers for use with the antibodiesin fluorescence polarisation immunoassays. The cpds. havedetectable fluorescence polarisation and are used to assaycompetition between phencyclidine and phencyclidine metabolites andas tracers for the recognition sites of the antibodies.Phencyclidine has potent analgesic and anaesthetic properties, and

    produces serious and prolonged post-anaesthetic confusion anddelirium.0/0

    FS CPI EPIFA ABMC CPI: B04-C01; B05-B01E; B05-B01H; B05-B01J; B05-B01M; B06-A03;

    B07-D05; B07-D11; B07-D12; B11-C08D3; B12-K04AEPI: S03-E14H4